Medigene AG (ETR:MDG1 – Get Free Report) dropped 0.3% on Friday . The company traded as low as €1.80 ($1.95) and last traded at €1.86 ($2.02). Approximately 2,385 shares were traded during trading, a decline of 99% from the average daily volume of 306,207 shares. The stock had previously closed at €1.87 ($2.03).
Medigene Trading Down 0.3 %
The firm has a market cap of $27.42 million, a PE ratio of -1.54, a price-to-earnings-growth ratio of 7.12 and a beta of 0.84. The company has a 50-day simple moving average of €1.83 and a 200 day simple moving average of €1.51. The company has a current ratio of 2.39, a quick ratio of 5.85 and a debt-to-equity ratio of 12.94.
Medigene Company Profile
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Featured Articles
- Five stocks we like better than Medigene
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Texas Roadhouse Stock Steering for New Highs This Year
- 3 Fintech Stocks With Good 2021 Prospects
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Do ETFs Pay Dividends? What You Need to Know
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.
